| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS | C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BLVD, SOUTH SAN FRANCISCO | /s/ Brett A. Grimaud, Attorney-in-Fact | 04 Jun 2025 | 0001898490 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TBPH | Ordinary Shares | Sale | $264,000 | -24,000 | -6.6% | $11.00 | 336,918 | 02 Jun 2025 | Direct |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
This transaction was executed in accordance with the reporting person's 10b5-1 plan dated 03/14/2024.